Abstracts & Presentations
Posters at ACC 09 -
Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindololin Moderate to Severe HF Patients, According to Pre-specified Statistical Analysis Plan
All-Cause Mortality Endpoint Comparison in Large Beta-Blocker Heart Failure Trials:United States (US) vs. Rest of World (ROW)
